PeptideInjectableImmunomodulatorBioregulator peptide

Livagen

Also known as KEDA peptide · Lys-Glu-Asp-Ala

Written by enwyReviewed 5 Aug 20261 sources0 comments

Livagen (Lys-Glu-Asp-Ala) is a synthetic Khavinson bioregulator peptide marketed for immune and gastrointestinal/hepatic support. Evidence comes only from preclinical chromatin-decondensation studies and Russian reports from the originating group; no independent human trials exist.

01 Overview

Livagen is a tetrapeptide bioregulator reported by Khavinson's group to decondense chromatin and activate ribosomal genes in lymphocytes, particularly in aged cells. This is proposed to restore transcriptional activity and immune function.\n\nThese are mechanistic and preclinical findings without independent human clinical validation. Livagen is sold as a research peptide.

02 Mechanism

Reported to bind DNA and decondense heterochromatin, reactivating silenced ribosomal genes in aged lymphocytes; human relevance unproven.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal	5–10 mcg/day	IM	Microgram Russian protocols; no clinical basis.

04 Effects

Effect	Magnitude	Evidence
Chromatin/gene reactivationDecondensed chromatin and reactivated ribosomal genes in cultured aged lymphocytes.	n/a	Preclinical
Immune supportClaimed immune benefits; unverified in humans.	n/a	Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Injection-site reactionLocal irritation at injection sites.	Mild	Common	Anecdotal
Unknown human safetyNo independent human toxicology data.	Moderate	Unquantified	Unconfirmed

06 Legal status

United States

Research chemical; not FDA-approved

Research use only. · as of Jan 2026

07 References

Livagen peptide decondenses chromatin in lymphocytes of old peopleBull Exp Biol Med, 2004

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.